Forbes contributors publish independent expert analyses and insights. Jesse Pines is an expert in healthcare innovation and wellness. This voice experience is generated by AI. Learn more. This voice ...

A single blood draw called Galleri, made by GRAIL, is designed to look for cancer signals from more than 50 cancer types ...

Points to one of the most talked-about advances in cancer screening: multi-cancer early detection blood tests.

A pioneering blood test designed to screen for more than 50 types of cancer, currently being evaluated by the NHS, has correctly identified the disease in nearly two-thirds of cases it flagged. The ...

According to the American Cancer Society, by 2023, there will be around 609,360 deaths due to cancer. Of course, there are several things people can do to help eliminate causes of cancer, such as ...

Multicancer blood tests have for years been hyped as a potential breakthrough in early cancer detection. But with news that one of the big names in the field, the Galleri test, failed to meet its ...

Many cancers do not exhibit symptoms and patients are unaware they have the disease until it has reached an advanced stage — but the Galleri test can change that. Galleri, which can detect cancer in ...

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter of 2026.

Despite a disappointing trial result, there's still a case for buying the stock, with a near-term catalyst on the horizon.